New combo tackles resistant cancers in small trial
NCT ID NCT03607890
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This study tests whether combining two immunotherapy drugs, nivolumab and relatlimab, can shrink or control advanced solid tumors with a specific genetic feature (MSI-H) that have stopped responding to prior PD-(L)1 therapy. About 38 adults with these hard-to-treat cancers will receive the drug combination. The main goal is to see how many patients' tumors shrink, while also monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MSI - H SOLID TUMORS PRIOR OF PD-(L) 1 THERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
Conditions
Explore the condition pages connected to this study.